Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus NUFYMCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus NUFYMCO.
AMPHOTEC vs NUFYMCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Category C
Category C
Antifungal
Antifungal